WO2013111578A1 - アルツハイマー病の診断方法、及び診断システム - Google Patents
アルツハイマー病の診断方法、及び診断システム Download PDFInfo
- Publication number
- WO2013111578A1 WO2013111578A1 PCT/JP2013/000311 JP2013000311W WO2013111578A1 WO 2013111578 A1 WO2013111578 A1 WO 2013111578A1 JP 2013000311 W JP2013000311 W JP 2013000311W WO 2013111578 A1 WO2013111578 A1 WO 2013111578A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tau protein
- intranasal
- value
- comparison
- alzheimer
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Definitions
- the present invention relates to a diagnostic method for diagnosing Alzheimer's disease (AD) using a specimen. More specifically, the present invention relates to a diagnostic method for realizing in vitro diagnosis using a sample collected from an AD patient or a healthy person who may have AD.
- AD Alzheimer's disease
- Alzheimer's disease is a disease characterized by progressive dementia that occurs from the early age to the old age.
- the number of patients in Japan is said to be over 1 million. In the future, the number is expected to increase steadily as the population ages.
- Clinical symptoms of Alzheimer's disease are memory impairment, higher brain memory impairment (aphasia, apraxia, agnosia, constitutional apraxia) and the like. The symptoms are often seen in other dementia diseases, and it is extremely difficult to make a definitive diagnosis of Alzheimer's disease based on clinical symptoms alone.
- Alzheimer's disease has never had a fundamental treatment until now, but since 1999, when vaccine therapy was successful in model mice, expectations for development of the fundamental treatment have increased (see Non-Patent Document 1). In order to effectively use the fundamental therapy, it is necessary to diagnose Alzheimer's disease at an early stage.
- senile plaques and neurofibrillary tangles are characteristic pathological findings of Alzheimer's disease.
- the former main component is an aggregate of amyloid beta peptide (hereinafter referred to as A ⁇ ) having a ⁇ sheet structure, and the latter is an excessively phosphorylated tau protein.
- a ⁇ amyloid beta peptide
- the amyloid hypothesis that accumulation of A ⁇ in the brain is the first serious pathological change is dominant (see Non-Patent Document 2).
- pathological tissue changes such as accumulation of A ⁇ in the brain and an increase in phosphorylated tau protein have begun long before clinical symptoms develop. Therefore, detection of A ⁇ or tau protein in the brain as a marker is one of early diagnosis methods for Alzheimer's disease.
- a compound that binds to senile plaques has been developed into a compound labeled with a radioactive substance or a substance that emits MR signals and administered to the body to develop amyloid imaging methods that image senile plaques in the brain. It is being advanced.
- simultaneous measurement of general clinical laboratory items by blood sampling may be used as a clinical indicator of cognitive dysfunction, for example, by measuring thyroid hormone in the blood.
- administration of the above-described compound may be exposed to the measurer, which is not preferable.
- the problem with the conventional example is that there is a risk of infection by sampling using a highly puncture needle. That is, since the substance to be collected is cerebrospinal fluid or blood, it was expected to be less dangerous without administering a toxic substance into the body, but it is intended to collect biological fluid circulating in the body. The risk of infection was high due to needle invasion.
- an object of the present invention is to provide a method for diagnosing Alzheimer's disease that can reduce the risk of infection by making the invasiveness as low as possible.
- the method for diagnosing Alzheimer's disease of the present invention comprises a pretreatment step of pretreating an intranasal sample collected from the nasal cavity, and tau protein and / or amyloid beta peptide (hereinafter referred to as “tau protein”) in the intranasal sample pretreated in the pretreatment step , A ⁇ ), a comparison step in which the value of the tau protein and / or the A ⁇ obtained in the detection step is compared with a predetermined value, and a result of comparison in the comparison step And a display step for displaying.
- the invasiveness can be reduced as much as possible, and the risk of infection can be reduced.
- FIG. (A) The figure which shows A ⁇ density
- A) The figure which shows the tau protein density
- a ⁇ in the nasal mucosa tissue was known, but it was thought that there was no possibility of detection from a sample in the nasal cavity because the concentration was extremely low.
- Tau protein is also known as a major biomarker of AD, but it has not been confirmed in nasal mucosal tissues other than immunohistological examination using antigen-antibody reaction, and should be detected from intranasal specimens. There were no researchers who thought about.
- the method for diagnosing Alzheimer's disease in an embodiment of the present invention includes a pretreatment step of pretreating an intranasal specimen collected from the nasal cavity, and tau protein and / or amyloid beta in the intranasal specimen pretreated in the pretreatment step.
- a detection step for detecting a peptide (hereinafter referred to as A ⁇ ) a comparison step for comparing the value of the tau protein and / or the A ⁇ obtained in the detection step with a predetermined value, and a comparison in the comparison step
- a display step for displaying the result.
- the pretreatment step includes an extraction step for eluting the intranasal sample attached to the collection device into the extract, a filtration step for fractionating the extracted solution containing the eluted intranasal sample, and a filtered solution.
- a concentration step of concentrating can be included.
- a filter capable of fractionation can be used.
- the concentration step may further include an optimization step in which the filtered solution is adjusted to a solution having conditions optimal for detection by neutralization or the like.
- an extract containing formic acid when detecting A ⁇ , an extract containing formic acid was used in the extraction step.
- a liquid containing a biological tissue for example, brain tissue or mucous membrane
- a measurement kit capable of reliably and quantitatively measuring A ⁇ monomer manufactured and sold by Wako Pure Chemical Industries, Ltd., an accurate amount of A ⁇ could not be measured.
- the present inventors tried a method of adding formic acid to a solution as a means of decomposing into A ⁇ monomer using aggregated A ⁇ prepared from a standard substance.
- Formic acid is generally used to solubilize and separate proteins contained in animal and human tissues, and proteins aggregated and adsorbed in tissues.
- the present inventors have found that when formic acid is allowed to act on a liquid that does not contain living tissue, that is, a soluble A ⁇ oligomer already dispersed in the liquid, the soluble A ⁇ oligomer is unraveled and becomes an A ⁇ monomer. I found it.
- the mechanism by which soluble A ⁇ oligomers become A ⁇ monomers is unclear, but in liquids, some of the soluble A ⁇ oligomers are reversibly partly dissociated from A ⁇ monomers. It is presumed that it contributes to the stabilization of A ⁇ monomer.
- formic acid was used as an additive for decomposing A ⁇ in the extraction step, but the additive is a general denaturing agent or solubilizing agent such as guanidine or solubilizing agent used as a means for denaturing proteins. It may be urea or the like.
- the detection step includes immunoassay using an antigen-antibody reaction with the substance to be measured as an antigen.
- the immunoassay is preferably an ELISA method.
- a method that can directly or indirectly detect a protein as a measurement target substance may be used.
- MS Mass Spectrometry
- MS / MS MS
- liquid chromatography is suitable.
- the amount may be compared with a predetermined amount.
- a calibration curve obtained from a standard concentration curve of the target tau protein or A ⁇ is prepared using values obtained by absorption, fluorescence, luminescence or electrochemical detection, and this is set as a predetermined value.
- the comparison step may be a step of comparing a value obtained by performing a reverse regression from the calibration curve and a value of tau protein or A ⁇ calculated based on the detection step.
- the logarithm of the amount of tau protein and / or the amount of A ⁇ is used as the value of tau protein and the value of A ⁇ . Good.
- the display process includes displaying numerical values, diagrams and pictures. This process is a process that can support human understanding in determining the degree of divergence between the calculated value and the predetermined value, and whether the calculated value has increased or decreased from the predetermined value. It is preferable.
- a calculation step of calculating the sum of the square of the calculated tau protein value and the square of the calculated A ⁇ value may be performed. That is, only this sum may be used as an output (result) of the calculation process, but calculation using other parameters may be performed on this sum, and a value obtained by calculating a square root or a multiplier on these values may be calculated. It may be output. What is necessary is just to make the output of these calculation processes the comparison object in a comparison process.
- the detection means for detecting tau protein and A ⁇ in the intranasal sample collected from the nasal cavity in a single diagnostic system obtained by the detection means Comparing means for comparing the values of the tau protein and the A ⁇ with predetermined values, respectively, and display means for displaying the result of comparison by the comparing means are included.
- the diagnostic system may further include a calculation unit that calculates the square of the sum of the square of the value of the tau protein obtained by the detection unit and the square of the value of the A ⁇ . The calculated value obtained by the above is used as the value of the tau protein and the A ⁇ in the comparison step.
- AD Probable AD (hereinafter referred to as AD) patients were determined based on the clinical diagnostic criteria for Alzheimer's disease of NINCDS-ADRDA Work Group.
- Probable AD patients dementia is confirmed by clinical examination, intelligence test (such as mini-mental state), and neuropsychological test.
- the classification includes patients with two or more cognitive impairments, patients with memorized and other cognitive impairments, patients with no consciousness impairment, and onset age 40-90 Among them, there are patients over 65 years of age and patients who have no brain diseases other than systemic diseases and Alzheimer's disease that cause dementia.
- findings to determine that the patient is an AD patient include progressive deterioration of language, motor activity, and cognitive impairment (aphasia, aphasia, and agnosia) and disturbances in daily living activities and behavioral patterns.
- aphasia, aphasia, and agnosia progressive deterioration of language, motor activity, and cognitive impairment
- disturbances in daily living activities and behavioral patterns include progressive deterioration of language, motor activity, and cognitive impairment (aphasia, aphasia, and agnosia) and disturbances in daily living activities and behavioral patterns.
- there may be a family history of similar diseases especially pathologically diagnosed as Alzheimer's disease).
- Example 1 In this example, 12 AD subjects were 64 to 92 years old and averaged 83.2 years. Nine non-AD subjects were 29 to 65 years old and averaged 41.3 years old. Among these subjects, 11 subjects from 64 to 92 years old averaged 83.7 years for non-AD subjects, and 4 subjects from 36 to 64 years old averaged 40 subjects for subjects who measured both A ⁇ and tau protein. I was 8 years old.
- the nasal mucosa tissue was abraded using a cotton swab, and the cotton balls with the nasal mucosa tissue adhered thereto were put into a microtube to which 270 ⁇ L of ultrapure water had been added in advance. And it cut
- the cotton swab is suitable for collecting a sample in the nasal cavity because it has low invasiveness and can scrape a narrow and narrow area.
- a sampling device such as a scoop or a container for sampling may be used instead of the cotton swab.
- a sampling device that can be inserted into the nasal cavity and can be collected after the invasiveness is equivalent to that of a cotton swab or paralyzed in the nasal cavity.
- a quantitative collection device that can collect a fixed amount of sample in the nostril from the nostril.
- a commercially available plastic shaft swab medical auxiliary swab HUBY-COTIX EM3-50S (manufactured by Sanyo Co., Ltd.) was used.
- Ultrapure water is chemically independent of pH, so the extract used to elute tau protein is ultrapure.
- the ultrapure water preferably has an absorbance (210 to 400 nm) of 0.01 or less and a total organic carbon (TOC) of 4 ppb or less.
- the cotton swab was pulled up so that the cotton ball floated from the ultrapure water, and the cotton ball was fixed to the microtube by a lid and centrifuged at 14000 g to dehydrate the cotton ball. Thereafter, a cotton swab was taken out from the microtube, and the solution in the microtube was repeatedly suspended by suction and discharge 30 times with a syringe equipped with a 27G needle. 40 ⁇ L of the suspended solution was used for DNA, electrolyte, and total protein measurements. 200 ⁇ L of the remaining solution was transferred to a test tube, 500 ⁇ L of 100% formic acid was added as an extract, stirred, and allowed to stand for 1 hour in a thermostatic layer kept at 70 ° C.
- the test tube was taken out from the thermostatic layer, and the solution was subjected to fractional filtration with a filter (NANOSEP 100K OMEGA (PALL): a filter that excludes proteins of 100 kDa or more and allows only proteins with a molecular weight of 100 kDa or less to pass through).
- the filtrate was transferred to a test tube and concentrated under reduced pressure using a centrifugal evaporator until the amount of the solution reached 20 ⁇ L.
- 480 ⁇ L of 1 mol / L Tris pH unadjusted was added to prepare a 500 ⁇ L solution.
- the pH of each solution was measured, and the success or failure of neutralization was recorded on a recording sheet. It was confirmed that the pH was in the range of about 7.0 to 8.6.
- the measurement of A ⁇ was carried out using an ELISA measurement kit for measuring A ⁇ (manufactured by Wako Pure Chemical Industries, Human / Rat ⁇ Amyloid42 ELISA Kit wako, High-Sensitive; product number 292-64501). Prior to the measurement, 0.05, 0.1, 0.2, 0.25, 1, 2, 2.5, 5, 10, and 10 were prepared using a standard solution of A ⁇ 42. Or 20 pM. After the preparation, 100 ⁇ L each of a solution for preparing a calibration curve and 1 mL of a measurement sample were added to the microtiter plate of the measurement kit.
- the measurement was performed according to the instructions for use of the measurement kit. After the measurement, the concentration of A ⁇ 42 (A ⁇ value) contained in each measurement sample was calculated using a calibration curve.
- each sample for measurement showed a value of A ⁇ 42 of 0.39 to 2.99 pM.
- the amount of A ⁇ contained in the nasal mucosa tissue that could not be measured normally could be measured.
- the A ⁇ amount contained in the nasal mucosa tissue is useful information for the diagnosis of Alzheimer's disease. It was.
- the nasal mucosa tissue was abraded using a cotton swab similar to the A ⁇ measurement, and the cotton ball to which the nasal mucosa tissue was attached was put into a microtube to which 150 ⁇ L of ultrapure water was added in advance. And it cut
- the cotton swab was pulled up, and the cotton ball was fixed to the microtube while being floated from the ultrapure water.
- the microtube was put into a centrifuge and centrifuged at normal pressure for 1 minute to dehydrate the cotton ball, and then the cotton swab was taken out from the microtube.
- the obtained solution is used as a sample for measuring tau protein.
- Measurement of tau protein was performed using an ELISA measurement kit for measuring tau protein (manufactured by Invitrogen, Tau (Total) Human ELISA Kit; product number KHB0041). Prior to measurement, prepare a calibration curve to 15.6, 31.2, 62.5, 125, 250, 500, 1000, or 2000 pg / mL using tau protein standard solution. did. After the preparation, 100 ⁇ L each of a solution for preparing a calibration curve and 1 mL of a measurement sample were added to the microtiter plate of the measurement kit.
- the measurement was performed according to the instructions for use of the measurement kit. After the measurement, the concentration of tau protein (tau protein value) contained in each measurement sample was calculated using a calibration curve.
- each measurement sample showed a tau protein value of 16.4 to 923.8 pM.
- the present inventors have succeeded in detecting for the first time the amount of tau protein contained in nasal mucosal tissue that was not even considered to be normally detectable. Furthermore, since there was a significant difference between the amount of tau protein in AD subjects and the amount of tau protein in non-AD subjects, the amount of tau protein contained in the nasal mucosal tissue is useful information for the diagnosis of Alzheimer's disease. It has been shown.
- FIG. 3 shows a plot of the data of each subject with the tau protein concentration obtained by the above measurement as the horizontal axis and the A ⁇ concentration as the axis.
- the square a of the sum of the square of (A ⁇ concentration) and the square of (log 10 (tau protein concentration)), that is, the distance from the origin can be expressed as an individual value of the subject. It is a calculated value that can be done.
- FIG. 5 shows the number of people at each level in which the level of Alzheimer's disease is divided into 6 stages based on the calculated value of a obtained in FIG. More specifically, the calculated values shown in FIG. 4 are classified into 6 levels (0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 10, 10 or more), and AD subjects are not classified.
- the number of persons corresponding to each level in each AD subject is shown in the upper table of FIG. In the middle of FIG. 5, the cumulative number of people is shown in order from the level “10 or higher”. That is, the number of calculation values “10 or more” is 3 AD subjects, 0 non-AD subjects, and the number of “8 or more” is 8 AD subjects, 0 non-AD subjects, and “6 or more”.
- the number of AD subjects was 11, 11 non-AD subjects, the number of “4 or more” was 11 AD subjects, the number of non-AD subjects was 3, and the numbers of “2 or more” and “0 or more” were AD subjects. There are 11 non-AD subjects and 4 people.
- the lower part of FIG. 5 shows a tpf value (true positive fraction) and an fpf value (false positive fraction) calculated from the cumulative number of people in the middle part.
- the tpf value is a true positive rate, and is a test performance index (value is 0 to 1) indicating the proportion of subjects judged to be positive positive among subjects judged to be positive (AD). .
- the fpf value is a false positive rate, and is a test performance index (value is 0 to 1) indicating the proportion of subjects judged to be negative (nonAD). .
- the result of the current fpf value is 0.00 when the calculated value is “10 or more” and “8 or more” as positive, 0.25 when “6 or more” is positive, and “4 or more”. Is 0.75 when positive, and “1.00” when “2 or more” and “0 or more” are positive.
- the fpf value is calculated in the case of six types in which the test values are “10 or more”, “8 or more”, “6 or more”, “4 or more”, “2 or more”, or “0 or more”.
- tpf values are shown as values on the horizontal axis and the vertical axis, respectively.
- these 6 points are connected with a curve.
- This curve is generally called an ROC curve indicating specificity.
- ROC curve when the distance from the point where the fpf value is 0 and the tpf value is 1 to the curve is short, that is, when the area below the ROC curve is close to 1, it is known that the measurement accuracy is high. Yes.
- Example 2 Next, in this example, 5 AD subjects (average 85.6 years), 5 elderly non-AD subjects (average 75.6 years), and 15 young non-AD subjects (average 33 years) were used as subjects. The results of further detailed investigation will be described with reference to FIG.
- the results of young non-AD subjects are concentrated in a low concentration range compared to the results of other subjects. What is important here is that even if an AD subject who is an elderly person with a relatively close age is compared with a non-AD subject, a relatively high concentration of subjects exists in the AD subject, so there is a significant difference. is there. That is, it is considered that measuring the intranasal A ⁇ concentration is useful for discriminating between healthy subjects and AD patients.
- intranasal tau protein that we newly discovered as a result of earnest research, it is very invasive compared to collecting cerebrospinal fluid by indexing the risk of developing Alzheimer's disease.
- a diagnostic method with low risk can be provided.
- the nasal cavity is close to the brain, the A ⁇ concentration and the tau protein concentration in the nasal cavity accurately and quickly reflect each concentration in the brain, and the effectiveness as a diagnostic method is improved.
- the present invention is useful as a method for diagnosing Alzheimer's disease.
- diagnosis does not include a specialized medical practice performed by a doctor, but includes various processes such as preprocessing, detection, comparison, and display using various instruments as described in the present embodiment. This is to support medical practice performed by doctors.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
本実施例では、AD被験者は64歳から92歳の12名で平均83.2歳であった。非AD被験者は29歳から65歳の9名で平均41.3歳であった。これらのうちAβとタウ蛋白の両方を測定した被験者については、AD被験者は64歳から92歳の11名で平均83.7歳、非AD被験者は36歳から64歳の4名で平均40.8歳であった。
次に、本実施例では、AD被験者5名(平均85.6歳)、高齢の非AD被験者5名(平均75.6歳)、若年の非AD被験者15名(平均33歳)を被験者として、さらに詳細に調査した結果について、図7を用いて説明する。
Claims (13)
- 鼻腔から採取した鼻腔内検体を前処理する前処理工程と、
前記前処理工程で前処理された鼻腔内検体中のタウ蛋白またはアミロイドベータペプチド(以下、Aβとする)を検出する検出工程と、
前記検出工程で得られた前記タウ蛋白または前記Aβの値を、予め定めた値と比較する比較工程と、
前記比較工程で比較された結果を表示する表示工程と、からなる、アルツハイマー病の診断方法。 - 前記前処理工程は、採取器具に付着した前記鼻腔内検体を抽出液中に溶出する抽出工程を含む、請求項1に記載のアルツハイマー病の診断方法。
- 前記前処理工程は、前記鼻腔内検体を含む前記抽出液を分画するろ過工程を含む、請求項2に記載のアルツハイマー病の診断方法。
- 前記ろ過工程において、分画できるフィルターを用いる、請求項3に記載のアルツハイマー病の診断方法。
- 前記抽出液は、前記鼻腔内検体中のタウ蛋白を検出するときは超純水である、請求項2ないし4のいずれか1項に記載のアルツハイマー病の診断方法。
- 前記抽出液は、前記鼻腔内検体中のAβを検出するときはギ酸である、請求項2ないし4のいずれか1項に記載のアルツハイマー病の診断方法。
- 前記鼻腔内検体は綿棒によって鼻腔内から採取されたものである、請求項1に記載のアルツハイマー病の診断方法。
- 前記鼻腔内検体は定量採取器具によって鼻腔内から採取されたものである、請求項1に記載のアルツハイマーの診断方法。
- 鼻腔から採取した鼻腔内検体を前処理する前処理工程と、
前記前処理工程で前処理された鼻腔内検体中のタウ蛋白およびAβを検出する検出工程と、
前記検出工程で得られた前記タウ蛋白および前記Aβの値を、それぞれ予め定めた値と比較する比較工程と、
前記比較工程で比較された結果を表示する表示工程と、からなる、アルツハイマー病の診断方法。 - 前記前処理工程は、採取器具に付着した前記鼻腔内検体を抽出液中に溶出する抽出工程を含み、前記抽出液は、前記鼻腔内検体中のタウ蛋白を検出するときは超純水であり、前記鼻腔内検体中のAβを検出するときはギ酸である、請求項9に記載のアルツハイマー病の診断方法。
- 前記検出工程で得られた前記タウ蛋白の値の2乗と前記Aβの値の2乗との和の平方を演算する演算工程をさらに有し、得られた演算値を、前記比較工程における前記タウ蛋白および前記Aβの値として使用する、請求項9に記載のアルツハイマー病の診断方法。
- 鼻腔から採取した鼻腔内検体中のタウ蛋白およびAβを検出する検出手段と、
前記検出手段で得られた前記タウ蛋白および前記Aβの値を、それぞれ予め定めた値と比較する比較手段と、
前記比較手段で比較された結果を表示する表示手段と、からなる、アルツハイマー病の診断システム。 - 前記検出手段で得られた前記タウ蛋白の値の2乗と前記Aβの値の2乗との和の平方を演算する演算手段をさらに有し、得られた演算値を、前記比較工程における前記タウ蛋白および前記Aβの値として使用する、請求項12に記載のアルツハイマー病の診断システム。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13741512.1A EP2808679A4 (en) | 2012-01-27 | 2013-01-23 | DIAGNOSTIC METHOD AND DIAGNOSTIC SYSTEM FOR ALZHEIMER'S DISEASE |
US14/374,181 US20150031054A1 (en) | 2012-01-27 | 2013-01-23 | Method and system for diagnosing alzheimer's disease |
JP2013555201A JP5850374B2 (ja) | 2012-01-27 | 2013-01-23 | アルツハイマー病の診断補助方法、及び診断システム |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012014796 | 2012-01-27 | ||
JP2012-014796 | 2012-01-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013111578A1 true WO2013111578A1 (ja) | 2013-08-01 |
Family
ID=48873308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/000311 WO2013111578A1 (ja) | 2012-01-27 | 2013-01-23 | アルツハイマー病の診断方法、及び診断システム |
Country Status (4)
Country | Link |
---|---|
US (1) | US20150031054A1 (ja) |
EP (1) | EP2808679A4 (ja) |
JP (1) | JP5850374B2 (ja) |
WO (1) | WO2013111578A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015180933A (ja) * | 2014-03-07 | 2015-10-15 | 国立大学法人鳥取大学 | 認知症予防システム |
JP2018169349A (ja) * | 2017-03-30 | 2018-11-01 | 国立大学法人滋賀医科大学 | アミロイドβ蛋白並びにタウ蛋白及び/又はリン酸化タウ蛋白の測定方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101868343B1 (ko) * | 2018-01-16 | 2018-06-18 | 재단법인대구경북과학기술원 | 콧물 시료의 베타 아밀로이드 올리고머를 이용한 알츠하이머 질환의 진행 단계 스크리닝용 조성물 및 이를 이용한 알츠하이머 질환의 진행 단계 스크리닝 방법 |
WO2021125732A1 (ko) * | 2019-12-19 | 2021-06-24 | 재단법인 대구경북과학기술원 | 콧물 시료를 이용한 경도 인지 장애의 진단용 바이오마커 조성물 및 이를 이용한 경도 인지 장애의 진단 방법 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10509797A (ja) | 1994-11-14 | 1998-09-22 | アセナ ニューロサイエンシーズ, インコーポレイテッド | アミロイドβペプチド(X−≧41)およびタウを測定することによりアルツハイマー病の診断を補助する方法 |
JP2002516853A (ja) * | 1998-06-01 | 2002-06-11 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 神経変性疾患の処置法 |
WO2011092796A1 (ja) * | 2010-01-28 | 2011-08-04 | パナソニック株式会社 | アミロイドβ測定方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6194217B1 (en) * | 1980-01-14 | 2001-02-27 | Esa, Inc. | Method of diagnosing or categorizing disorders from biochemical profiles |
WO1992013273A1 (en) * | 1991-01-18 | 1992-08-06 | Esa, Inc. | Method of diagnosing or categorizing disorders from biochemical profiles |
US20130231588A1 (en) * | 2011-07-21 | 2013-09-05 | Panasonic Corporation | Biological tissue collecting tool and biological tissue collection method using the same |
-
2013
- 2013-01-23 US US14/374,181 patent/US20150031054A1/en not_active Abandoned
- 2013-01-23 WO PCT/JP2013/000311 patent/WO2013111578A1/ja active Application Filing
- 2013-01-23 EP EP13741512.1A patent/EP2808679A4/en not_active Withdrawn
- 2013-01-23 JP JP2013555201A patent/JP5850374B2/ja not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10509797A (ja) | 1994-11-14 | 1998-09-22 | アセナ ニューロサイエンシーズ, インコーポレイテッド | アミロイドβペプチド(X−≧41)およびタウを測定することによりアルツハイマー病の診断を補助する方法 |
JP2002516853A (ja) * | 1998-06-01 | 2002-06-11 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 神経変性疾患の処置法 |
WO2011092796A1 (ja) * | 2010-01-28 | 2011-08-04 | パナソニック株式会社 | アミロイドβ測定方法 |
Non-Patent Citations (6)
Title |
---|
HARDY JA; SELKOSE DF, SCIENCE, vol. 297, 2002, pages 353 - 356 |
HIROYASU AKATSU ET AL.: "Hito Hana Nenmaku-Shukyu ni Okeru Ap Kaiseki to Shindan no Kanosei", DEMENT JPN, vol. 26, no. 4, 15 October 2012 (2012-10-15), pages 509, XP008172180 * |
KAMESHIMA N ET AL.: "Correlation of A.BETA. deposition in the nasal cavity with the formation of senile plaques in the brain of a transgenic mouse model of Alzheimer's disease", NEUROSCI LETT, vol. 513, no. 2, April 2012 (2012-04-01), pages 166 - 169, XP028477392 * |
SCHENK D; SEUBERT P ET AL., NATURE, vol. 400, 1999, pages 173 - 177 |
See also references of EP2808679A4 |
SHIGERU TAKAMI: "Recent progress in cell biological studies of human nasal chemosensory receptor cells", THE JAPANESE JOURNAL OF TASTE AND SMELL RESEARCH, vol. 5, no. 2, 1998, pages 97 - 108, XP008172144 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015180933A (ja) * | 2014-03-07 | 2015-10-15 | 国立大学法人鳥取大学 | 認知症予防システム |
JP2018169349A (ja) * | 2017-03-30 | 2018-11-01 | 国立大学法人滋賀医科大学 | アミロイドβ蛋白並びにタウ蛋白及び/又はリン酸化タウ蛋白の測定方法 |
Also Published As
Publication number | Publication date |
---|---|
EP2808679A4 (en) | 2015-01-14 |
US20150031054A1 (en) | 2015-01-29 |
JPWO2013111578A1 (ja) | 2015-05-11 |
JP5850374B2 (ja) | 2016-02-03 |
EP2808679A1 (en) | 2014-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20170023591A1 (en) | Traumatic Brain Injury and Neurodegenerative Biomarkers, Methods, and Systems | |
JP6106277B2 (ja) | 尿中エキソソームmRNAおよびそれを用いて糖尿病性腎症を検出する方法 | |
JP6927212B2 (ja) | 軽度認知障害又はアルツハイマー型認知症の評価方法 | |
US20130045542A1 (en) | New formulations for diagnosis of alzheimer's disease | |
JP2007024822A (ja) | 男性の更年期又はうつ病の鑑別方法 | |
JP5850374B2 (ja) | アルツハイマー病の診断補助方法、及び診断システム | |
EP2530464A1 (en) | Amyloid measurement method | |
WO2022039191A1 (ja) | 軽度認知障害の試験方法、軽度認知障害の試験試薬、および軽度認知障害の治療薬候補物質のスクリーニング方法 | |
JP4200187B2 (ja) | 腎臓のクリアランスを決定する方法 | |
JP6883847B2 (ja) | アミロイドβ蛋白並びにタウ蛋白及び/又はリン酸化タウ蛋白の測定方法 | |
TWI735470B (zh) | 糖尿病性腎病之判定方法、及於此種判定方法中生物標記之用途 | |
JP5106631B2 (ja) | アルツハイマー病の検査方法 | |
RU2706537C1 (ru) | Способ оценки риска развития осложнений в раннем послеоперационном периоде у больных с дисплазией соединительной ткани | |
JP2012122788A (ja) | アディポネクチン及び/又はインスリンの測定方法 | |
RU2696485C2 (ru) | Способ диагностирования in vitro болезни Альцгеймера на основании редокс-статуса альбумина в спинномозговой жидкости | |
Gautam et al. | Assessment and correlation of uric acid concentration in saliva and serum of patients attending tertiary care centre | |
Liang et al. | Development and validation of a novel ICP-MS method to quantify different copper species in human plasma from patients with Wilson disease | |
RU2490636C1 (ru) | Способ диагностики степени поражения тубулоинтерстициальной ткани почек у больных с хронической сердечной недостаточностью | |
RU2642723C2 (ru) | Способ выявления больных с впервые возникшими приступами острой порфирии | |
JP4464298B2 (ja) | 尿中のn2,n2−ジメチルグアノシン濃度測定による心疾患の診断方法 | |
US20170181686A1 (en) | Breath test for assessing liver disease | |
US20220196682A1 (en) | Catecholamine concentrations in a blood sample and arterial hypertension status in a subject for a differential diagnosis of neurodegenerative diseases including alzheimer's disease | |
Şambel et al. | Serum Mindin, Nephrin and Podocalyxin Levels in Patients with Type 1 Diabetes: Are These New Markers to Detect the Development of Nephropathy? | |
Mhlana et al. | Distal renal tubular acidosis in a patient with Hashimoto’s thyroiditis: a case report | |
JP2640970B2 (ja) | アミロイド及びアミロイド様物質の測定法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13741512 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2013555201 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14374181 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2013741512 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013741512 Country of ref document: EP |